They found that, indeed, there was a modest beneficial effect on kidney function even in people without kidney disease, and a larger beneficial effect in slowing rate of kidney function loss in people with kidney disease, explains Shuchi Anand, MD, MS, an associate professor of medicine (nephrology) at Stanford Medicine
In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided
Currently approved GLP-1 receptor agonists in the United States include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Bydureon BCise)
Ozempic, Mounjaro and Zepbound are not approved for any pediatric use